Update – Institutional research on Citius Pharma just issued by Dawson James Securities. Citius Pharmaceuticals
Positive Phase 3 FDA Trial Results, Low Float Biotech, Trading Below Book Value
Citius Pharma is commercializing critical care drug Mino-Lok.
“The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the U.S. and approximately $1.5 billion per year worldwide.”
Good day everyone,
We are updating information on a company we’ve covered before, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR). The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; Mino Wrap, used in breast reconstruction surgery; and Halo-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Current price $.60 per share
Float (est.) 14 million shares
Book value $ .84 per share
52-week range $.40 to $1.79 per share
Mino-Lok is the lead product at Citius and is a combination of three compounds, already approved by the FDA to treat infected central venous catheters (CVC). Mino-Lok is designed to avoid the standard care of removing and replacing an infected CVC, a costly and oftentimes dangerous procedure.
Mino-Lok was developed by the MD Anderson Cancer Center, one of the top cancer treatment centers in the USA for decades. Citius has a license to develop the product.
Yesterday, the company announced a positive outcome of the pre-specified interim futility analysis for the Phase 3 clinical trial of Mino-Lok® vs. standard-of-care antibiotic locks. The analysis was conducted by the Mino-Lok trial Data Monitoring Committee, an independent panel of experts charged with periodically monitoring the safety and efficacy of the progress of the pivotal trial.
The positive data from this analysis is a big milestone for CTXR and may act as a catalyst for the company’s shares.
None of the clinical trials, to date, have indicated any adversities. In fact, all clinical trials to date have indicated virtually 100% efficacy.
Topline data from the superior efficacy interim analysis, the next major milestone in the Mino-Lok trial, is expected in the first half of 2020.
The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the U.S. and approximately $1.5 billion per year worldwide.
Mino-Wrap (new product for 2019) is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries. Mino-Wrap provides more durable antimicrobial protection of the implant-tissue interface than peri-operative irrigation with antibiotic solutions (the current standard of care). CTXR plans to communicate further developments in the Mino-Wrap program after they secure and have a pre-IND meeting with FDA.
The company recently expanded their relationship with MD Anderson Cancer Center for a worldwide license for Mino-Wrap.
Halo Lido is a formulation of two compounds (already FDA approved) for the treatment of hemorrhoids.
There is no prescription strength medicine for the treatment of hemorrhoids. Recently the company, with advice from the FDA reformulated Halo-Lido based on results from an initial Phase II study. A toxicology study will be initiated by year-end ahead of an expanded Phase II study to start in 2020.
Indicators of a bullish outlook for CTXR shares:
This year the insiders at Citius Pharmaceuticals purchased over four million shares of the company stock at an average price over $1.00 per share. There were no insider sales. In fact, there have been no insider sales in the past two years. The executives at Citius seem to have a bullish outlook for the company.
Two Wall Street analysts have issued ratings and price targets for Citius Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 747.46%. The high price target for CTXR is $7.00 and the low-price target for CTXR is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
CTXR shares are trading at 72% of their book value. A gain just to book value would be 40%.
In September, just three months ago, Citius Pharmaceuticals shares were trading at $1.35 per share. A return to that price level would represent a gain of 225%.
We see many other development stage biotech companies with lofty share prices like TG Therapeutics ($9.85) or Relmada Therapeutics ($43.47), similar in development stage to CTXR, and realize what a bargain Citius shares might be.
One of the more compelling reasons to get in on CTXR shares and Mino-Lok may be HOW the product works. Humans are increasingly encountering infections caused by bacteria that antibiotics aren’t effective against. Part of the reason for that is a biofilm that bacteria forms around itself to keep the antibiotics away. The first thing the Mino-Lok compounds do is dissolve that biofilm.
The implications and potentials of that process are immeasurable.
The Traders News Group
______________________
Privacy Policy and Disclosure
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
Google, as a third party vendor, uses cookies to serve ads on your site. Google’s use of the DART cookie enables it to serve ads to your users based on their visit to your sites and other sites on the Internet. Users may opt out of the use of the DART cookie by visiting the Google ad and content network privacy policy.
TradersNewsSource.com website does not collect cookies on site visitors. Please be advised our site content does include links to third party sites and our site does not have any control over their privacy policy.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Disclaimer
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated six thousand dollars cash via bank wire by venado media llc for this week’s coverage of CTXR. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
